ViGenCell Inc. Logo

ViGenCell Inc.

Developing T-cell immune therapies to treat cancer and other incurable diseases.

308080 | KO

Overview

Corporate Details

ISIN(s):
KR7308080001
LEI:
Country:
South Korea
Address:
서울특별시 금천구 가산로9길 66 더리즌밸리 지식산업센터(가산동), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ViGenCell Inc. is a biotechnology company specializing in the research and development of immune cell therapies. The company develops novel treatments for cancers and other incurable diseases, aiming to prolong life expectancy and enhance patient quality of life. Its core technology includes ViTier, a proprietary T-cell therapy platform that employs antigen-specific killer T cells to target and eliminate pathogens or tumor cells. Founded in 2013 as the first subsidiary of the Catholic University Technology Holdings, ViGenCell leverages clinically validated research to advance its therapeutic pipeline.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등거래계획보고서
Korean 40.7 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.2 MB
2025-04-30 00:00
Regulatory News Service
기타경영사항(자율공시) (iPSC(유도만능줄기세포) 유래 NK세포치료제 공동개발계약 체결)
Korean 6.8 KB
2025-04-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-04-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-03-28 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 12.6 KB
2025-03-27 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 33.6 KB
2025-03-27 00:00
Board/Management Information
대표이사변경
Korean 10.6 KB
2025-03-19 00:00
Audit Report / Information
감사보고서제출
Korean 25.3 KB
2025-03-19 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 395.3 KB
2025-03-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-03-13 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 90.2 KB
2025-03-12 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 818.4 KB
2025-03-11 00:00
Share Issue/Capital Change
주식매수선택권행사
Korean 17.9 KB

Automate Your Workflow. Get a real-time feed of all ViGenCell Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ViGenCell Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ViGenCell Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

AIM ImmunoTech Inc. Logo
Develops immuno-therapeutics for cancers, immune disorders, and viral diseases.
United States of America
AIM
AKANDA CORP. Logo
Cultivates and distributes pharma-quality medical cannabis for patients in legal markets worldwide.
United States of America
AKAN
Akari Therapeutics Plc Logo
A clinical-stage oncology company developing next-gen ADCs for targeted cancer therapy.
United States of America
AKTX
Akebia Therapeutics, Inc. Logo
Developing and commercializing novel, FDA-approved therapeutics for kidney disease.
United States of America
AKBA
Akero Therapeutics, Inc. Logo
A clinical-stage biotech developing therapies for serious metabolic diseases like MASH.
United States of America
AKRO
Alaunos Therapeutics, Inc. Logo
Developing TCR-T cell therapies to treat solid tumors by targeting specific cancer mutations.
United States of America
TCRT
Aldeyra Therapeutics, Inc. Logo
Biotech developing therapies for ocular and systemic immune-mediated inflammation.
United States of America
ALDX
Alector, Inc. Logo
Pioneers immuno-neurology therapies for neurodegenerative diseases like Alzheimer's.
United States of America
ALEC
Aligos Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel oral therapies for liver and viral diseases.
United States of America
ALGS
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark
ALK

Talk to a Data Expert

Have a question? We'll get back to you promptly.